The change of ownership clause in the contract between Johnson & Johnson (J&J) and Schering-Plough over the control of two key products, Remicade® and golimumab, could be a stumbling block in the merger between Merck and Schering-Plough. Merck’s acquisition has been structured as a reverse merger to side-step the clause but J&J could still have its say in the deal.